Drugs / NCR300
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05371730 | May 2022 → May 2025 | myelodysplastic syndrome | Nuwacell Biotechnologies Co., Ltd. | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06441084 | Jun 2024 → Dec 2028 expected | acute myeloid leukemia | Nuwacell Biotechnologies Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCR300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05371730 ↗ |
| Route | Intravenous | “Intravenous infusion of NK cells（NCR300）” NCT05371730 ↗ |